Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma

BACKGROUND: Subgroup analyses of the NAPOLI‐1 study identified that among patients who were irinotecan naïve prior to entering the clinical trial, a survival benefit was observed between the study arm and control arm. This treatment benefit was not observed among those previously exposed to irinotec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Kenneth H., Cockrum, Paul, Surinach, Andy, Lamarre, Neil, Wang, Shu, O'Reilly, Eileen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166959/
https://www.ncbi.nlm.nih.gov/pubmed/36934451
http://dx.doi.org/10.1002/cam4.5714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166959/
https://www.ncbi.nlm.nih.gov/pubmed/36934451
http://dx.doi.org/10.1002/cam4.5714

Ejemplares similares